| Original language | English |
|---|---|
| Pages (from-to) | 244-246 |
| Number of pages | 3 |
| Journal | Neuropsychopharmacology |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2009 |
Bibliographical note
Funding Information:This work was supported by NIH U19 DA017548, K02 DA00399, T32 DA007304.
Funding Information:
In addition to income received from his primary employer, Dr Robert Pechnick has received financial support from Sepracor Inc and Forest Laboratories Inc. Except for income received from her primary employer, Dr Vera Chesnokova declares that no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service. For either investigator there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. This work was partially support by a NARSAD Young Investigator Award (VC), National Institutes of Health Grants MH079988 (VC), MH078037 (RNP) and MH079370 (RNP), and the Levine Family Fund Research Endowment (RNP).
ASJC Scopus subject areas
- Pharmacology
- Psychiatry and Mental health
